Oncology & Cancer

The targeted drug olutasidenib is highly effective in certain patients with myelodysplastic syndrome (MDS), a condition considered incurable without transplantation, according to a new clinical study led by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

Green tea and red wine may seem like simple dietary choices—but beneath the surface, they harbor compounds with remarkable medical potential. Scientists are uncovering how these everyday drinks might support cancer treatment, not by replacing conventional therapies like chemotherapy or radiotherapy, but by enhancing their effectiveness and reducing their side-effects.

A Northeastern University researcher has identified a way to target two of the deadliest cancer types, melanoma and triple negative breast cancer, with chemotherapy drugs but without the harms associated with chemotherapy.

Prostate cancer is one of the most common cancers in the world. While many prostate cancers grow slowly and remain localized, other types are aggressive and spread quickly. That’s why Dr. Carlos Vargas, a Mayo Clinic radiation oncologist, encourages regular screening. He says the goal of screening is to detect prostate cancer early, when it’s still confined to the prostate gland and has the best chance for successful treatment.

Australian researchers have discovered a promising new strategy to suppress the growth of aggressive and hard-to-treat cancers by targeting a specialized molecular process known as “minor splicing.”

Researchers have discovered a way to make the immune system’s T cells significantly more effective at fighting cancer. By blocking a protein called Ant2, they were able to reprogram how these cells consume and generate energy—essentially rewiring their internal power supply.

Patients face high out-of-pocket costs (OOPCs) after an incident diagnosis of cancer, with costs increasing with stage of diagnosis, according to a study published in JAMA Network Open.

Accurate removal of tumors is the most critical aspect of cancer surgery, yet it remains a significant challenge in clinical practice. In breast cancer, for example, the positive margin rate—where cancer cells remain at the surgical boundary—can reach up to 35%, often requiring reoperation and increasing the risk of recurrence.

As far back as the 4th Century B.C., Aristotle marveled at the nimble gecko’s ability to “run up and down a tree in any way, even with the head downwards.”

Tracking race-specific rates of cancer incidence and mortality is important for identifying racial differences in these outcomes and for monitoring efforts aimed at achieving the highest level of health for all.